Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia
Acta Haematologica · 24.06.2025 · 149 (1) · 24-38
DOI: 10.1159/000547026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Haematologica, online erschienen am 24.06.2025. Verfasst von Anna Torrent und 1 weiteren Autor:innen. Beteiligte Einrichtung: ICO Badalona, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelo…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Philadelphia Chromosome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 134 Literaturangaben.
Abstract (Originalsprache)
Background: Philadelphia chromosome-positive acute lymphoblastic leukemia has historically been associated with poor prognosis and limited therapeutic options. Over the past 2 decades, however, the treatment paradigm has markedly shifted. Summary: The introduction of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, and ponatinib, has revolutionized frontline therapy, significantly improving remission rates and long-term survival. These agents, when combined with reduced-intensity chemotherapy or even with corticosteroids, have enabled less toxic regimens, particularly beneficial for older or unfit patients. The implementation of measurable residual disease monitoring has emerged as a pivotal tool for risk stratification and therapeutic decision-making. Consequently, the role of allogeneic hematopoietic stem cell transplantation, considered a cornerstone of curative treatment, is being reevaluated in patients achieving sustained deep molecular responses. More recently, immunotherapeutic strategies – including the bispecific T-cell engager blinatumomab and chimeric antigen receptor (CAR) T-cell therapies – have emerged as effective alternatives to conventional chemotherapy and TKIs. Key Messages: While TKIs remain the backbone of treatment, the integration of immunotherapeutic strategies – including bispecific antibodies and CAR T-cell therapy – has expanded therapeutic options, not only in the R/R setting but increasingly in frontline regimens. Ongoing research aimed at optimizing the sequencing, combination, and duration of these therapies is essential to further enhance clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICO Badalona, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Barcelona, Spain, atorrent@iconcologia.net.
- ICO Badalona, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Barcelona, Spain.
Zitieren
APA
Torrent, A., & Ribera, J. M. (2025). Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia. Acta Haematologica, 149(1), 24-38. https://doi.org/10.1159/000547026
Vancouver
Torrent A, Ribera JM. Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia. Acta Haematologica. 2025;149(1):24-38. doi:10.1159/000547026
BibTeX
@article{Torrent2025,
author = {Torrent, Anna and Ribera, Josep Maria},
title = {Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia},
journal = {Acta Haematologica},
year = {2025},
volume = {149},
number = {1},
pages = {24--38},
doi = {10.1159/000547026}
}
EUVIMED